靶向PCSK9治疗在心血管领域的最新进展

The latest advances in targeting PCSK9 therapy in the cardiovascular field

摘要:

前蛋白转化酶枯草溶菌素9(PCSK9)可以调节低密度脂蛋白胆固醇(LDLC)水平,其功能失调与动脉粥样硬化及心血管疾病的发生发展密切相关。研究证实,PCSK9抑制剂降脂力度强,且具有良好的安全性和耐受性,靶向抑制PCSK9的新方法正处于临床不同开发阶段。本综述总结了PCSK9主要的作用机制及其对心血管系统的影响,重点阐述了目前靶向PCSK9降脂治疗的新兴策略。

Abstract:

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can modulate low density lipoprotein cholesterol (LDLC) levels, and its dysfunction is closely associated with the progression of atherosclerosis and cardiovascular diseases.Research has shown that PCSK9 inhibitors are highly effective in lowering lipids and have good safety and tolerability. New approaches to targeting PCSK9 inhibition are currently in different stages of clinical development. This review outlines the primary mechanisms of PCSK9 and its impact on the cardiovascular system,emphasizing the current emerging strategies for targeting PCSK9 in lipid-lowering treatments.